Clinical trials
Completed trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
6,902 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 20 |
| 2001 | 55 |
| 2002 | 65 |
| 2003 | 116 |
| 2004 | 143 |
| 2005 | 167 |
| 2006 | 241 |
| 2007 | 262 |
| 2008 | 287 |
| 2009 | 309 |
| 2010 | 335 |
| 2011 | 363 |
| 2012 | 360 |
| 2013 | 317 |
| 2014 | 352 |
| 2015 | 382 |
| 2016 | 360 |
| 2017 | 394 |
| 2018 | 386 |
| 2019 | 415 |
| 2020 | 328 |
| 2021 | 398 |
| 2022 | 279 |
| 2023 | 247 |
| 2024 | 185 |
| 2025 | 72 |
| 2026 | 14 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6,902 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 273 |
| Pfizer | 247 |
| AstraZeneca | 228 |
| Novartis Pharmaceuticals | 222 |
| GlaxoSmithKline | 219 |
| Eli Lilly and Company | 175 |
| Bristol-Myers Squibb | 161 |
| Sanofi | 157 |
| Bayer | 149 |
| Janssen Research & Development, LLC | 141 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 281 |
| Arthritis, Rheumatoid | 221 |
| Asthma | 192 |
| Carcinoma, Non-Small-Cell Lung | 162 |
| Breast Neoplasms | 148 |
| Pulmonary Disease, Chronic Obstructive | 142 |
| Diabetes Mellitus | 127 |
| Heart Failure | 121 |
| Colitis, Ulcerative | 115 |
| Neoplasms | 106 |
Trials
Showing 76 to 100 of 6,902. Each trial links to its page on Pharma Observatory.
6,802 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.